Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Lawrence Green

Procedural Dermatology Rockville, MD Medical Doctor

NPI 1073581344 CMS profile 93488

15005 Shady Grove Rd, Suite 440, Rockville, MD 20850

Open in the dashboard

General payments

$1,075,300

1,410 records reported · program years 2019–2025

Research payments

$883,458

Paid to them · 49 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$1,935,533 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Lawrence Green of Rockville, MD is reported in the CMS Open Payments database as having received $1,075,300 across 1,410 general payments and $883,458 in research payments paid to them. Separately, studies naming them as principal investigator received $1,935,533 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Procedural Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $76,062 150
2025 Research $353,142 19
2024 General $181,759 271
2024 Research $157,290 16
2023 General $164,514 250
2023 Research $30,469 7
2022 General $158,236 199
2021 General $60,427 100
2020 General $99,371 105
2020 Research $894 1
2019 General $334,931 335
2019 Research $341,663 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Lawrence Green
  • Procedural Dermatology median
  • Middle half of Procedural Dermatology
  • National median

In program year 2025, general payments to Lawrence Green were reported at $76,062. Among 381 Procedural Dermatology profiles paid that year, the median was $592 and the middle half received between $144 and $1,778.

Show as a table
Year Lawrence Green Procedural Dermatology median Middle half National median
2019 $334,931 $454 $152–$1,260 $163
2020 $99,371 $243 $90–$835 $114
2021 $60,427 $337 $102–$1,128 $132
2022 $158,236 $443 $119–$1,654 $149
2023 $164,514 $583 $137–$1,838 $160
2024 $181,759 $611 $132–$1,835 $164
2025 $76,062 $592 $144–$1,778 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Amgen Inc. $128,419 121 payments
  2. E.R. Squibb & Sons, L.L.C. $98,789 117 payments
  3. UCB, Inc. $98,107 125 payments
  4. Incyte Corporation $91,880 131 payments
  5. Sun Pharmaceutical Industries Inc. $89,413 85 payments
  6. Celgene Corporation $78,141 73 payments
  7. Ortho Dermatologics, a division of Bausch Health US, LLC $74,809 98 payments
  8. AbbVie, Inc. $74,566 98 payments
  9. Galderma Laboratories, L.P. $55,271 101 payments
  10. Dermavant Sciences, Inc. $39,206 64 payments
  11. Other $246,699 397 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $609,344 207 payments
  2. Consulting Fee $169,693 70 payments
  3. Honoraria $122,227 35 payments
  4. Travel and Lodging $90,643 307 payments
  5. Food and Beverage $39,553 771 payments
  6. Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program $32,300 10 payments
  7. Compensation for serving as faculty or as a speaker for a medical education program $11,350 3 payments
  8. Gift $117 1 payment
  9. Education $73 6 payments
Products named General payments · program years 2019–2025
  1. Otezla Inflammation $110,591 101 payments
  2. OPZELURA $91,312 120 payments
  3. Otezla Dermatology $77,409 69 payments
  4. ILUMYA $65,710 55 payments
  5. SOTYKTU $58,138 78 payments
  6. VTAMA $54,224 83 payments
  7. SKYRIZI $48,522 51 payments
  8. Bimzelx $45,171 59 payments
  9. AKLIEF $38,737 28 payments
  10. DUOBRII $28,867 42 payments
  11. Other $386,288 631 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Takeda Pharmaceuticals U.S.A., Inc. $464,393 29 payments
  2. Celgene Corporation $302,137 1 payment
  3. E.R. Squibb & Sons, L.L.C. $56,850 3 payments
  4. Eli Lilly and Company $33,340 6 payments
  5. Arcutis Biotherapeutics, Inc. $19,553 9 payments
  6. Novartis Pharmaceuticals Corporation $7,186 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

57

Median for Dermatology: 534

Drug cost

$2,737

Median for Dermatology: $67,151

Branded share of claims

0%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clindamycin Phosphate Generic 13 $2,208
Gentamicin Sulfate Generic 12 $394
Triamcinolone Acetonide Generic 32 $134

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 45 billing codes

Paid by Medicare

$69,515

Medicare's payments for the services billed

Medicare patients

354

Average age 75

Services billed

1,083

149 women, 205 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 68%
Arthritis 41%
Ischemic heart disease 27%
Diabetes 24%
Cancer 20%
Chronic kidney disease 16%
Osteoporosis 16%
Atrial fibrillation 15%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OPZELURA
$40,145 — —
Bimzelx
$27,188 — —
Otezla
$20,857 — —
Zoryve
$10,374 — —
Cabtreo
$10,066 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

1,459 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Procedural Dermatology in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record